D S Hoon

Summary

Affiliation: John Wayne Cancer Institute
Country: USA

Publications

  1. ncbi Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial
    Sojun Hoshimoto
    John Wayne Cancer Institute at Saint John s Health Center, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
    J Clin Oncol 30:3819-26. 2012
  2. ncbi Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment
    Yusuke Sato
    Department of Molecular Oncology, John Wayne Cancer Institute at Saint John s Health Center, 2200 Santa Monica Blvd, Santa Monica, CA, 90404, USA
    Cancer Microenviron 2:205-14. 2009
  3. ncbi Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors
    Eiji Sunami
    Department of Molecular Oncology, The John Wayne Cancer Institute, Saint John s Health Center, Santa Monica Blvd, Santa Monica, California 90404, USA
    Breast Cancer Res 10:R46. 2008
  4. ncbi Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow
    D S Hoon
    Department of Molecular Oncology, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
    Am J Pathol 159:493-500. 2001
  5. ncbi Are circulating tumor cells an independent prognostic factor in patients with high-risk melanoma?
    Dave S B Hoon
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, CA 90404, USA
    Nat Clin Pract Oncol 1:74-5. 2004
  6. ncbi Molecular mechanisms of metastasis
    Dave S B Hoon
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, CA 90404, USA
    Cancer Metastasis Rev 25:203-20. 2006
  7. ncbi Molecular mechanisms of metastasis
    Dave S B Hoon
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California 90404, USA
    J Surg Oncol 103:508-17. 2011
  8. ncbi Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients
    Dave S B Hoon
    Department Molecular Oncology, John Wayne Cancer Institute at Saint John s Health Center, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
    Oncogene 23:4014-22. 2004
  9. ncbi Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients?
    D S Hoon
    John Wayne Institute for Cancer Treatment and Research, Saint John s Hospital, Santa Monica, CA 90404, USA
    J Clin Oncol 16:1430-7. 1998
  10. ncbi Molecular staging of early colon cancer on the basis of sentinel node analysis: a multicenter phase II trial
    A J Bilchik
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, CA 90404, USA
    J Clin Oncol 19:1128-36. 2001

Research Grants

  1. DNA Markers As Surrogates:Melanoma Patient Response
    Dave Hoon; Fiscal Year: 2007

Detail Information

Publications90

  1. ncbi Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial
    Sojun Hoshimoto
    John Wayne Cancer Institute at Saint John s Health Center, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
    J Clin Oncol 30:3819-26. 2012
    ....
  2. ncbi Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment
    Yusuke Sato
    Department of Molecular Oncology, John Wayne Cancer Institute at Saint John s Health Center, 2200 Santa Monica Blvd, Santa Monica, CA, 90404, USA
    Cancer Microenviron 2:205-14. 2009
    ..This review discusses how carcinogenesis, cancer progression, and site-specific metastasis are related to interactions between cancer cells, immune cells, and DAMPs through TLR activation in the tumor microenvironment...
  3. ncbi Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors
    Eiji Sunami
    Department of Molecular Oncology, The John Wayne Cancer Institute, Saint John s Health Center, Santa Monica Blvd, Santa Monica, California 90404, USA
    Breast Cancer Res 10:R46. 2008
    ....
  4. ncbi Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow
    D S Hoon
    Department of Molecular Oncology, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
    Am J Pathol 159:493-500. 2001
    ..GalNAc-T mRNA provides a specific and sensitive molecular marker for RT-PCR/ECL detection of infrequent neuroblastoma cells in BM...
  5. ncbi Are circulating tumor cells an independent prognostic factor in patients with high-risk melanoma?
    Dave S B Hoon
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, CA 90404, USA
    Nat Clin Pract Oncol 1:74-5. 2004
  6. ncbi Molecular mechanisms of metastasis
    Dave S B Hoon
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, CA 90404, USA
    Cancer Metastasis Rev 25:203-20. 2006
    ..The hope is that further unraveling of the direct and indirect molecular events of lymphatic metastasis will lead to new approaches in developing effective therapeutics...
  7. ncbi Molecular mechanisms of metastasis
    Dave S B Hoon
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California 90404, USA
    J Surg Oncol 103:508-17. 2011
    ....
  8. ncbi Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients
    Dave S B Hoon
    Department Molecular Oncology, John Wayne Cancer Institute at Saint John s Health Center, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
    Oncogene 23:4014-22. 2004
    ..Our findings indicate that the incidence of TSG hypermethylation increases during tumor progression. Methylation of TSG may play a significant role in cutaneous melanoma progression...
  9. ncbi Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients?
    D S Hoon
    John Wayne Institute for Cancer Treatment and Research, Saint John s Hospital, Santa Monica, CA 90404, USA
    J Clin Oncol 16:1430-7. 1998
    ....
  10. ncbi Molecular staging of early colon cancer on the basis of sentinel node analysis: a multicenter phase II trial
    A J Bilchik
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, CA 90404, USA
    J Clin Oncol 19:1128-36. 2001
    ..We hypothesized that multimarker reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of sentinel lymph nodes (SNs) draining a primary CRC could detect micrometastases not detected by conventional histopathologic analysis...
  11. ncbi Molecular detection of metastatic melanoma cells in cerebrospinal fluid in melanoma patients
    D S Hoon
    Department of Molecular Oncology, Division Medical Oncology, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, California 90404, USA
    J Invest Dermatol 117:375-8. 2001
    ..04). Fifteen of 37 patients (41%) had either positive MRI and/or positive RT-PCR results. Multimarker RT-PCR is more informative and sensitive than cytology/IHC in assessing the CSF of melanoma patients...
  12. ncbi Functional interleukin 4 receptor and interleukin 2 receptor common gamma-chain on human non-small cell lung cancers: novel targets for immune therapy
    R Essner
    Department of Molecular Oncology, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA, USA
    J Thorac Cardiovasc Surg 119:10-20. 2000
    ..We examined signal transduction pathways used by the interleukin 4 receptor that may account for growth arrest of the cell line LUst but had no effect on another non-small cell lung cancer cell line, SK-MES-1...
  13. ncbi Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients
    B Taback
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint John's Health Center, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
    Cancer Res 61:5723-6. 2001
    ..CONCLUSIONS: This study provides evidence that blood testing for circulating tumor genetic markers may provide valuable prognostic information and guide future therapy...
  14. ncbi Detection of MAGE-A3 in breast cancer patients' sentinel lymph nodes
    R A Wascher
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, CA 90404, USA
    Br J Cancer 85:1340-6. 2001
    ..One half of breast tumours expressed MAGE-A3 mRNA, which has important potential implications for antigen-specific targeted immunotherapy...
  15. ncbi Molecular strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes
    I Miyashiro
    Department of Molecular Oncology, John Wayne Cancer Clinic, Division Gastrointestinal Surgery, and Joyce Eisenberg Keefer Breast Center, John Wayne Cancer Institute, Santa Monica, CA 90404, USA
    Clin Chem 47:505-12. 2001
    ..CONCLUSIONS: The uMAGE-A reverse transcription-PCR/ECL assay provides a practical and sensitive approach for detection of various metastatic cancers in tissues and blood...
  16. ncbi CpG island methylator phenotype predicts progression of malignant melanoma
    Atsushi Tanemura
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, California 90404, USA
    Clin Cancer Res 15:1801-7. 2009
    ..Because epigenetic inactivation of TRGs also has been shown in malignant melanoma, we hypothesized the existence of a clinically significant CIMP in cutaneous melanoma progression...
  17. ncbi Prognostic relevance of occult nodal micrometastases and circulating tumor cells in colorectal cancer in a prospective multicenter trial
    Kazuo Koyanagi
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California 90404, USA
    Clin Cancer Res 14:7391-6. 2008
    ..Nodal micrometastasis and circulating tumor cells detected by multimarker quantitative real-time reverse transcription-PCR (qRT-PCR) may have prognostic importance in patients with colorectal cancer...
  18. ncbi Human high molecular weight-melanoma-associated antigen: utility for detection of metastatic melanoma in sentinel lymph nodes
    Yasufumi Goto
    Department of Molecular Oncology, John Wayne Cancer Institute, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
    Clin Cancer Res 14:3401-7. 2008
    ..Immunohistochemical staining (IHC) using S-100p-HMB-45-, and MART-1-specific antibodies is used for detecting metastases in sentinel lymph nodes (SLN). However, improvement in IHC is needed for melanoma micrometastasis detection...
  19. ncbi Molecular markers in malignant cutaneous melanoma: gift horse or one-trick pony?
    Steve R Martinez
    Department of Molecular Oncology, John Wayne Cancer Institute, 2200 Santa Monica Boulevard, Santa Monica, California 90404, USA
    J Cell Biochem 96:473-83. 2005
    ....
  20. ncbi Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients
    Kazuo Koyanagi
    Department of Molecular Oncology, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA 90404, USA
    Clin Chem 51:981-8. 2005
    ..0001). CONCLUSIONS: Multimarker qRT can detect circulating melanoma cells in blood. Measurement of the studied molecular markers in blood may be useful in detection of metastasis and monitoring treatment response of melanoma patients...
  21. ncbi Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial
    Kazuo Koyanagi
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, CA 90404, USA
    J Clin Oncol 23:8057-64. 2005
    ..6; 95% CI, 3.16 to 50.5; P = .0003). CONCLUSION: Serial monitoring of CTCs in blood may be useful for indicating systemic subclinical disease and predicting outcome of patients receiving neoadjuvant BC for metastatic melanoma...
  22. ncbi Clinicopathological utility of molecular staging for melanoma patients undergoing sentinel lymphadenectomy
    Hiroya Takeuchi
    Department of Molecular Oncology, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, California, USA
    Ann Surg Oncol 11:152S-5S. 2004
    ..The molecular detection of occult metastasis in PE SLNs has significant clinicopathologic and logistic advantages over molecular analysis of frozen SLNs...
  23. ncbi Molecular clonality of in-transit melanoma metastasis
    T Nakayama
    Department of Molecular Oncology, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 904304, USA
    Am J Pathol 158:1371-8. 2001
    ..Based on LOH analysis, in-transit metastases are clonal in origin. The establishment of clinically successful in-transit melanoma metastasis requires specific genetic events that seem to be unique and homogeneous for each patient...
  24. ncbi Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas
    D D Chi
    National Genetics Institute, Los Angeles, California, USA
    Am J Pathol 150:2143-52. 1997
    ..These studies demonstrate that melanomas and primary brain tumors express common MAAs and could be exploited in patients with malignant glioma by active specific immunotherapy against these common MAAs...
  25. ncbi Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine
    Hiroya Takeuchi
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, CA 90404, USA
    Int J Cancer 117:1032-8. 2005
    ..Overall, the study indicates survivin expression in metastatic melanomas can significantly influence disease outcome and patient responses to immunotherapy...
  26. ncbi Molecular upstaging of sentinel lymph nodes in melanoma: where are we now?
    Steve R Martinez
    Department of Molecular Oncology, John Wayne Cancer Institute at St John s Health Center, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
    Surg Oncol Clin N Am 15:331-40. 2006
    ..Molecular approaches have made a major impact on the field of infectious disease and should one day be of equal usefulness in the diagnosis of cancer...
  27. ncbi Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients
    Hiroya Takeuchi
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint John's Health Center, Santa Monica, CA 90404, USA
    J Clin Oncol 22:2671-80. 2004
    ..CONCLUSION: Molecular upstaging of PE histopathology-negative SLNs by multiple-marker qRT assay is a significant independent prognostic factor for long-term disease recurrence and overall survival of patients with early-stage melanoma...
  28. ncbi Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine
    Robert A Wascher
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint John's Health Center, Santa Monica, CA 90404, USA
    J Clin Oncol 21:2558-63. 2003
    ....
  29. ncbi Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease
    B Taback
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California 90404, USA
    Cancer Res 61:8845-50. 2001
    ..018). A multimarker reverse transcription-PCR assay that correlates with known clinicopathological prognostic parameters may have potential clinical utility by monitoring tumor progression with a blood test...
  30. ncbi Pathologic examination of sentinel lymph node for breast carcinoma
    R R Turner
    Department of Surgery, John Wayne Cancer Institute, 2200 Santa Monica Boulevard, Santa Monica California 90404, USA
    World J Surg 25:798-805. 2001
    ..This review discusses our current understanding of the pathologic and molecular techniques for sentinel node examination...
  31. ncbi Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma
    Minoru Kitago
    Department of Molecular Oncology, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, California, USA
    Clin Cancer Res 15:2988-94. 2009
    ..Aberration in RUNX3 expression has not been described for cutaneous melanoma. Therefore, we assessed the expression of RUNX3 in cutaneous melanoma and its regulatory mechanisms relative to tumor progression...
  32. ncbi Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma
    Mia Spugnardi
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, California 90404, USA
    Cancer Res 63:1639-43. 2003
    ..Our findings indicate that the RASSF1A gene is turned off in a significant number of melanomas and that CpG promoter region hypermethylation may play a role in the transcriptional inactivation of the RASSF1A gene in malignant melanoma...
  33. ncbi The use of molecular profiling of early colorectal cancer to predict micrometastases
    Anton J Bilchik
    Department of Molecular Oncology, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
    Arch Surg 137:1377-83. 2002
    ..Lymphatic mapping followed by focused analysis of the sentinel node is highly accurate in identifying micrometastases...
  34. ncbi Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial
    Anton J Bilchik
    Department of Gastrointestinal Oncology, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA 90404, and Michigan State University McLaren Regional Medical Center, Flint, MI, USA
    Ann Surg 246:568-75; discussion 575-7. 2007
    ..6% rate of micrometastases (MM) identified by immunohistochemical staining (IHC) of H&E-negative SNs in CC. We hypothesized that these MM have prognostic importance...
  35. ncbi Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes
    Donald L Morton
    John Wayne Center Institute, Santa Monica, CA 90404, USA
    Ann Surg 236:438-48; discussion 448-9. 2002
    ....
  36. ncbi Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma
    Kazuo Koyanagi
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California 90404, USA
    Clin Cancer Res 16:2402-8. 2010
    ....
  37. ncbi Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients
    Kazuo Koyanagi
    Department of Molecular Oncology, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA 90404, USA
    Clin Cancer Res 12:1137-43. 2006
    ....
  38. ncbi Prospective multicenter trial of staging adequacy in colon cancer: preliminary results
    Anton J Bilchik
    John Wayne Cancer Institute and Saint Johns Health Center, Santa Monica, CA 90404, USA
    Arch Surg 141:527-33; discussion 533-4. 2006
    ..A 25% recurrence rate in patients with node-negative CRC suggests that current staging practices are inadequate. Focused analysis of the sentinel node (SN) by multiple sectioning and immunohistochemistry improves staging accuracy...
  39. ncbi Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas
    Hiroya Takeuchi
    Department of Molecular Oncology, Saint John's Health Center, Santa Monica, California 90404, USA
    Cancer Res 63:441-8. 2003
    ..The studies also imply that an assessment of melanoma tumor MAAs may provide a stratification factor targeted for active-specific immunotherapy...
  40. ncbi Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells
    Takuji Mori
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California, 90404, USA
    Cancer Res 65:1800-7. 2005
    ..This increase in chemokine receptor expression correlated with functional activity. Most importantly, we have identified an epigenetic mechanism that may endogenously regulate chemokine receptor expression on melanoma cells...
  41. ncbi Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma
    Akihide Fujimoto
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint John s Health Center, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
    Cancer Res 64:2245-50. 2004
    ..In summary, the study demonstrates that allelic imbalance in the 12q22-23 region is a genomic surrogate of poor disease outcome for cutaneous melanoma patients...
  42. ncbi Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases
    Donald L Morton
    Roy E Coats Research Laboratories of the John Wayne Cancer Insstitute at Saint John s Health Center, Santa Monica, CA 90404, USA
    Ann Surg 238:538-49; discussion 549-50. 2003
    ....
  43. ncbi CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells
    Hiroya Takeuchi
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California 90404, USA
    Clin Cancer Res 10:2351-8. 2004
    ..We hypothesized that CCL21/SLC regulates the migration of CCR7-bearing melanoma cells from a primary lesion to regional tumor-draining lymph nodes...
  44. ncbi Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes
    Christine T Kuo
    Department of Molecular Oncology, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
    J Clin Oncol 21:3566-72. 2003
    ..More significantly, identification of molecular risk factors can be detected in histopathologically negative SLNs for distinguishing early-stage melanoma patients with a worse prognosis...
  45. ncbi c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases
    Hiroya Takeuchi
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California 90404, USA
    Clin Cancer Res 9:1480-8. 2003
    ..CONCLUSIONS: This study indicates c-MET mRNA overexpression in primary CRC may be an important prognostic marker for early stage invasion and regional disease metastasis...
  46. ncbi Microsatellite alterations detected in the serum of early stage breast cancer patients
    B Taback
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California 90404, USA
    Ann N Y Acad Sci 945:22-30. 2001
    ....
  47. ncbi Functional interleukin-4 receptor and interleukin-2 receptor common gamma chain in human gastric carcinoma: a possible mechanism for cytokine-based therapy
    R Essner
    Department of Molecular Oncology, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
    J Gastrointest Surg 5:81-90. 2001
    ..These receptors may represent novel targets for directing cytokine-based therapy...
  48. ncbi Identification of a quantitative MINT locus methylation profile predicting local regional recurrence of rectal cancer
    Michiel F G de Maat
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California 90404, USA
    Clin Cancer Res 16:2811-8. 2010
    ..In this study, we evaluated the significance of a quantitative epigenetic multimarker panel analysis of primary tumors to predict local recurrence in rectal cancer patients from a retrospective multicenter clinical trial...
  49. ncbi Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma
    Yasufumi Goto
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California, USA
    J Invest Dermatol 130:221-9. 2010
    ..FABP7 may function as a tumor progression gene and can be used as a potential diagnostic biomarker of early-stage melanoma systemic spreading in blood...
  50. ncbi LC/MS-based quantitative proteomic analysis of paraffin-embedded archival melanomas reveals potential proteomic biomarkers associated with metastasis
    Sharon K Huang
    Department of Molecular Oncology, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, California, United States of America
    PLoS ONE 4:e4430. 2009
    ....
  51. ncbi Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes
    Taku Nakagawa
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, California 90404, USA
    Clin Cancer Res 13:4105-10. 2007
    ....
  52. ncbi Estrogen receptor-alpha methylation predicts melanoma progression
    Takuji Mori
    Department of Molecular Oncology, Division of Surgical Oncology, John Wayne Cancer Institute, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
    Cancer Res 66:6692-8. 2006
    ..004] and overall survival (RR, 2.31; 95% CI, 1.41-5.58; P = 0.003) in biochemotherapy patients. Hypermethylated ER-alpha is a significant factor in melanoma progression. Serum methylated ER-alpha is an unfavorable prognostic factor...
  53. ncbi Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival
    Joseph Kim
    Department of Molecular Oncology, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
    J Clin Oncol 23:2744-53. 2005
    ..The CXCR4-CXCL12 signaling mechanism may be clinically relevant for patients with CRC and represents a potential novel target for disease-directed therapy...
  54. ncbi Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis
    Masaru Shinozaki
    Department of Molecular Oncology, John Wayne Cancer Institute and St. John's Health Center, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
    Clin Cancer Res 11:2156-62. 2005
    ....
  55. ncbi Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas
    Masaru Shinozaki
    Department Molecular Oncology, Saint John s Health Center, Santa Monica, California 90404, USA
    Clin Cancer Res 10:1753-7. 2004
    ..Somatic mutations of BRAF kinase, a component of the Ras-mitogen-activated protein/extracellular signal-regulated kinase kinase-mitogen-activated protein kinase pathway, are frequently reported (>65%) in nevi and malignant melanomas...
  56. ncbi Peptide nucleic acid clamp PCR: a novel K-ras mutation detection assay for colorectal cancer micrometastases in lymph nodes
    Bret Taback
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, CA 90404, USA
    Int J Cancer 111:409-14. 2004
    ..This study demonstrates the utility, specificity and sensitivity of PNA clamp PCR assay in identifying occult micrometastases in the SLN of CRC patients by single-base mutation analysis...
  57. ncbi Detection of differentially expressed proteins in early-stage melanoma patients using SELDI-TOF mass spectrometry
    Lori L Wilson
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint John's Health Center, Santa Monica, California 90404, USA
    Ann N Y Acad Sci 1022:317-22. 2004
    ..This novel pilot study revealed three proteins that accurately identified patients who developed recurrence after curative resection of primary melanoma...
  58. ncbi X-Linked inhibitor of apoptosis protein expression level in colorectal cancer is regulated by hepatocyte growth factor/C-met pathway via Akt signaling
    Hiroya Takeuchi
    Department of Molecular Oncology, Gastrointestinal Section, Santa Monica, CA 90404, USA
    Clin Cancer Res 11:7621-8. 2005
    ..We hypothesized that the hepatocyte growth factor (HGF) activation in colorectal cancer via c-Met receptor regulates IAP proteins through Akt signaling...
  59. ncbi Quantification of circulating DNA in the plasma and serum of cancer patients
    Bret Taback
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California 90404, USA
    Ann N Y Acad Sci 1022:17-24. 2004
    ..Significant consideration must be given to the methods by which circulating nucleic acids are obtained for clinical analysis...
  60. ncbi Multimarker circulating DNA assay for assessing blood of prostate cancer patients
    Eiji Sunami
    Department of Molecular Oncology and the Breast and Endocrine Program, John Wayne Cancer Institute, Saint John s Health Center, Santa Monica, CA 90404, USA
    Clin Chem 55:559-67. 2009
    ..We hypothesized that circulating multimarker DNA assays detecting both genetic and epigenetic markers in serum would be useful in assessing PCa patients...
  61. ncbi Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients
    Kazuo Koyanagi
    Department of Molecular Oncology, John Wayne Cancer Institute at Saint John's Health Center, CA 90404, USA
    Cancer Res 66:6111-7. 2006
    ....
  62. ncbi Cytotoxic T lymphocytes that recognize decameric peptide sequences of retinoblastoma binding protein 1 (RBP-1) associated with human breast cancer
    T Takahashi
    Department of Biotechnology Sciences, John Wayne Cancer Institute, Santa Monica, CA 90404, USA
    Br J Cancer 81:342-9. 1999
    ..RBP-1 peptide antigens may be of clinical significance as a potential peptide vaccine against human breast cancer...
  63. ncbi Functional RET G691S polymorphism in cutaneous malignant melanoma
    N Narita
    Department of Molecular Oncology, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA 90404, USA
    Oncogene 28:3058-68. 2009
    ..The study demonstrates that RETp is frequently found in cutaneous melanoma, particularly desmoplastic subtypes, and responds to GDNF inducing events favorable for tumor progression...
  64. ncbi Molecular diagnosis of micrometastasis in the sentinel lymph node
    Hiroya Takeuchi
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint John's Health Center, Santa Monica, California 90404, USA
    Cancer Treat Res 127:221-52. 2005
  65. ncbi Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer
    Eiji Sunami
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California, USA
    Ann N Y Acad Sci 1137:171-4. 2008
    ..This preliminary study demonstrates the potential clinical utility of LINE1 copy numbers in breast cancer patients...
  66. ncbi Induction of a systemic immune response by a polyvalent melanoma-associated antigen DNA vaccine for prevention and treatment of malignant melanoma
    Maki Tanaka
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California 90404, USA
    Mol Ther 5:291-9. 2002
    ..01) controlled, and survival was prolonged compared with controls. These studies demonstrate that the polyvalent DNA vaccine induces an effective systemic Th response...
  67. ncbi Quantitative analysis of methylation of genomic loci in early-stage rectal cancer predicts distant recurrence
    Michiel F G de Maat
    Department of Molecular Oncology, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
    J Clin Oncol 26:2327-35. 2008
    ..We then explored in a different clinical patient group whether these epigenetic changes could be correlated with clinical outcome...
  68. ncbi Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine
    Farin F Amersi
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, California 90404, USA
    Clin Cancer Res 14:638-45. 2008
    ..The integrin heterodimers alphabeta are also known to be important mediators of cellular adhesion. We hypothesize that the mechanism of small intestinal metastasis by melanoma is via the CCR9-CCL25 axis and specific integrins...
  69. ncbi mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads
    Minoru Kitago
    Department of Molecular Oncology, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA 90404, USA
    Clin Chem 55:757-64. 2009
    ..The assessment of CTCs from blood has been difficult because of lack of a good monoclonal antibody (mAb) directed against surface cell antigens to capture melanoma cells...
  70. ncbi Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy
    Takuji Mori
    Department of Molecular Oncology, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA 90404, USA
    J Clin Oncol 23:9351-8. 2005
    ..38; 95% CI, 1.16 to 4.86; P = .018; odds ratio = 0.21; 95% CI, 0.05 to 0.90; P = .036). CONCLUSION: Detection of circulating methylated DNA in serum can predict response to BC and disease outcome...
  71. ncbi Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats
    Naoyuki Umetani
    Department of Molecular Oncology and Division of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, CA 90404, USA
    Clin Chem 52:1062-9. 2006
    ..78 and 0.80, respectively. CONCLUSIONS: Direct ALU-qPCR is a robust, highly sensitive, and high-throughput method to measure serum DNA integrity. DNA integrity is a potential serum biomarker for detection and evaluation of CRC and PACs...
  72. ncbi The clinical significance of MAGEA3 expression in pancreatic cancer
    Joseph Kim
    Gastrointestinal Research Section, Department of Molecular Oncology, John Wayne Cancer Institute, Saint John's Health Center, Santa Monica, CA 90404, USA
    Int J Cancer 118:2269-75. 2006
    ..Molecular assessment for MAGEA3 should be considered to improve prognostic evaluation and to identify eligible patients for potential immune-based therapy...
  73. ncbi Detection of mitochondrial DNA alterations in plasma of malignant melanoma patients
    Hiroya Takeuchi
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint John's Health Center, Santa Monica, California 90404, USA
    Ann N Y Acad Sci 1022:50-4. 2004
    ..However, circulating mtDNA alterations were more frequent in advanced disease. Studies indicate that circulating mtDNA mutations in the plasma of melanoma patients can be detected...
  74. ncbi Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome
    Joseph Kim
    Department of Molecular Oncology, Gastrointestinal Cancer Section, John Wayne Cancer Institute, Saint John's Health Center, Santa Monica, CA 90404, USA
    Ann Surg 244:113-20. 2006
    ..Quantitative analysis of CXCR4 gene expression in patients with liver metastases has prognostic significance for disease outcome...
  75. ncbi Prediction of breast tumor progression by integrity of free circulating DNA in serum
    Naoyuki Umetani
    Department of Molecular Oncology and the Joyce Eisenberg Breast Center, John Wayne Cancer Institute, Santa Monica, CA 90404, USA
    J Clin Oncol 24:4270-6. 2006
    ..0002 and P < .0001, respectively). CONCLUSION: Integrity of serum circulating DNA is a promising molecular biomarker for detecting breast cancer tumor progression and regional LN metastases...
  76. ncbi Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma
    Joseph Kim
    Department of Molecular Oncology, John Wayne Cancer Institute at Saint Johns Hospital, Santa Monica, CA 90404, USA
    Ann Surg 244:799-804. 2006
    ..To define the role of BRAF gene mutation in the progression of papillary thyroid carcinoma...
  77. ncbi Comparative analysis of mesenteric and peripheral blood circulating tumor DNA in colorectal cancer patients
    Bret Taback
    Department of Molecular Oncology, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
    Ann N Y Acad Sci 1075:197-203. 2006
    ..The findings provide important evidence supporting the origin of tumor-associated DNA in circulation, which merits consideration when devising blood-based nucleic acid assays for the assessment of CRC...
  78. ncbi Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy
    Masaru Shinozaki
    Department of Molecular Oncology, Division of Surgical Oncology, John Wayne Cancer Institute at Saint John s Health Center and The Angeles Clinic and Research Institute, Santa Monica, California 90404, USA
    Clin Cancer Res 13:2068-74. 2007
    ..We hypothesized that circulating serum B-RAFmt (B-RAFsmt) at V600E, detected in serum, predicts response in melanoma patients receiving concurrent biochemotherapy...
  79. ncbi Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer
    Naoyuki Umetani
    Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, CA 90404, USA
    Oncogene 24:4721-7. 2005
    ..ID4 mRNA level was suppressed in hypermethylated cancer specimens (P=0.014). ID4 may play an important suppressive role in tumor progression, and its silencing by hypermethylation may increase the risk of regional lymph node metastasis...
  80. ncbi Allelic imbalance of APAF-1 locus at 12q23 is related to progression of colorectal carcinoma
    Naoyuki Umetani
    Department of Molecular Oncology, John Wayne Cancer Institute, Saint Johns Health Science Center, Santa Monica, CA 90404, USA
    Oncogene 23:8292-300. 2004
    ..MIN was observed in 11 of 49 (23%) primary CRCs and was a favorable prognostic factor. Our results suggest that APAF-1 gene haploinsufficiency caused by AI increases with tumor progression, and relates to hepatic metastasis...
  81. ncbi Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis
    Naoyuki Umetani
    Department of Molecular Oncology, and Division of Gastrointestinal Oncology, John Wayne Cancer Institute, Santa Monica, California 90404, USA
    Clin Cancer Res 10:7475-83. 2004
    ..The epigenetic inactivation of ID4 gene on colorectal cancer (CRC) development and its clinical significance was assessed...
  82. ncbi Overexpression of beta 1,4N-acetylgalactosaminyl- transferase mRNA as a molecular marker for various types of cancers
    Yurika Sugita
    Department of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan
    Oncology 62:149-56. 2002
    ..CONCLUSION: Our results suggest that the RT-PCR assay for GalNAcT mRNA could be a potentially useful molecular marker for detecting cancer dissemination in blood circulation of patients with malignancy...
  83. ncbi Effects of chemokines on tumor metastasis
    Hiroya Takeuchi
    Department of Surgery, Keio University School of Medicine, Tokyo, Japan
    Cancer Treat Res 135:177-84. 2007
  84. ncbi Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta-analysis of prognosis
    Simone Mocellin
    Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova, Italy
    J Clin Oncol 25:1588-95. 2007
    ..However, no consensus exists on the clinical implementation of this prognostic indicator for the management of these patients...
  85. ncbi False negative sentinel lymph node biopsies in melanoma may result from deficiencies in nuclear medicine, surgery, or pathology
    Rooshdiya Z Karim
    Department of Anatomical Pathology, Sydney Cancer Centre, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
    Ann Surg 247:1003-10. 2008
    ..To investigate a cohort of melanoma patients with false negative (FN) sentinel node (SN) biopsies (SNBs) to identify the reasons for the FN result...
  86. ncbi Epigenetic analysis of body fluids and tumor tissues: application of a comprehensive molecular assessment for early-stage breast cancer patients
    Bret Taback
    Division of Surgical Oncology, Columbia University Medical Center, New York, New York 10032, USA
    Ann N Y Acad Sci 1075:211-21. 2006
    ..This study demonstrates the novel finding of tumor-associated epigenetic markers in BM aspirates/blood and their potential role as targets for molecular detection...
  87. ncbi The role of estrogen receptor in melanoma
    Atsushi Tanemura
    John Wayne Cancer Institute, Department of Molecular Oncology, 2200 Santa Monica Blvd, Santa Monica, CA 90404, USA
    Expert Opin Ther Targets 11:1639-48. 2007
    ..Possibilities and limitations of using ER as a therapeutic target in the treatment of melanoma is also discussed...
  88. ncbi Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma
    Bret Taback
    Department of Molecular Oncology, John Wayne Cancer Institute and Saint John's Health Center, Santa Monica, CA 90404, USA
    J Natl Cancer Inst 96:152-6. 2004
    ..003). Circulating tumor DNA markers may be useful in assessing prognosis for advanced melanoma patients and their response to biochemotherapy...
  89. ncbi Methylation of p16 and Ras association domain family protein 1a during colorectal malignant transformation
    Naoyuki Umetani
    Department of Molecular Oncology, John Wayne Cancer Institute, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
    Mol Cancer Res 4:303-9. 2006
    ..It allows detailed, intratumoral analysis of methylation heterogeneity within solid tumors. On-slide SBM will significantly improve our approach and understanding of epigenetic events in minimal disease and the carcinogenic process...
  90. ncbi Assessment of methylation events during colorectal tumor progression by absolute quantitative analysis of methylated alleles
    Michiel F G de Maat
    Department of Molecular Oncology, John Wayne Cancer Institute, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA
    Mol Cancer Res 5:461-71. 2007
    ....

Research Grants2

  1. DNA Markers As Surrogates:Melanoma Patient Response
    Dave Hoon; Fiscal Year: 2007
    ..The R33 phase will focus on validating the PGMs and determining their clinical utility in an ongoing prospective multicenter Phase II BC and maintenance Biotherapy trial for AJCC stage IV melanoma patients. ..